Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 1021-1026

  Ali, Muhammad A ^a   Rosati, Rita ^a   Pettit, George R ^b   Kalemkerian, Gregory P ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Apoptosis; Bcl 2; Dolastatin; Experimental therapeutics; Small cell lung cancer

Indexed keywords

DOLASTATIN; DOLASTATIN 10; DOLASTATIN 15; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG POTENCY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SMALL CELL; CELL CYCLE; DEPSIPEPTIDES; HUMANS; LUNG NEOPLASMS; OLIGOPEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0031865656     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boetner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB and Bontems RJ: The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109: 6883-6885, 1987.
2. Pettit GR, Kamano Y, Dufresne C, Cerny RL, Herald CL and Schmidt JM: Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Org Chem 54: 6005-6006, 1989.
3. Hu ZB, Gignac SM, Quentmeier H, Pettit GR and Drexler HG: Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leukemia Res 17: 333-339, 1993.
4. Beckwith M, Urba WJ and Longo DL: Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85: 483-488, 1993.
5. Winterhalter BR, Berger DP, Pettit GR and Fiebig HH: Cytotoxicity of dolastatin 10, dolastatin 15 and dolastatin K333 in human tumor xenografts in vitro. Proc Am Assoc Cancer Res 32: 402, 1991.
6. Quentmeier H, Brauer S, Pettit GR and Drexler HG: Cytostatic effects of dolastatin 10 and dolastatin 15 on human leukemia cell lines. Leukemia Lymphoma 6: 245-250, 1992.
7. Steube KG, Grunicke D, Pietsch T, Gignac SM, Pettit GR and Drexler HG: Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells. Leukemia 6: 1048-1053, 1992.
8. Bai R, Friedman SJ, Pettit GR and Hamel E: Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Biochem Pharmacol 43: 2637-2645, 1993.
9. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1995.
10. Reed JC: bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clinics North Am 9: 451-473, 1995.
11. Vaux DL, Cory S and Adams JM: bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
12. Hashimoto H, Chatterjee S and Berger N: Inhibition of etoposide-induced DNA recombination and mutant frequency by bcl-2 protein overexpression. Cancer Res 55: 4029-4035, 1995.
13. Haldar S, Jena N and Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
14. Haldar S, Chintapalli J and Croce C: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
15. Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res 56: 1851-1854, 1996.
16. Ikegaki N, Katsumata M, Minna J and Tsujimoto Y: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54: 6-8, 1994.
17. Ben-Ezra JM, Kornstein MJ, Grimes MM and Krystal G: Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 145: 1036-1040, 1994.
18. Higashiyama M, Doi O, Kodama K, Yokouchi H and Tateishi R: High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res 15: 503-505, 1995.
19. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Ohta S and Saijo N: Apoptosis of lung cancer cells caused by some anti-cancer agents is inhibited by bcl-2. Biochem Biophys Res Comm 192: 30-36, 1993.
20. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA and Zangemeister-Wittke U: Induction of apoptosis in small-cell lung cancer by an antisense oligonucleotide targeting the bel-2 coding sequence. J Natl Cancer Inst 89: 1027-1036, 1997.
21. Kalemkerian GP, Ou X, Adil MR, Rosati R, Khoulani MM, Madan SK and Pettit GR: Activity of dolastatin 10 against small cell lung cancer in vitro and in vivo: induction of apoptosis and phosphorylation of bcl-2. Clin Cancer Res (in press).
22. Vindelov L and Christensen IJ: An integrated set of methods for routine flow cytometric DNA analysis. In: Flow cytometry (Darzynkiewicz ZB and Crissman HA, eds). San Diego, Academic Press, 1990, pp 127-137.
23. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DGI, Higgs PI, Neckers L and Fojo T: Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57: 130-135, 1997.
24. Haldar S, Basu A and Croce C: bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.